Français
Contact us
Help
Search
Canada Site
A-Z Index
Consultations
Media Room
It's Your
Health
Home
About Health Canada
Consumer Product Safety
Diseases & Conditions
Drugs & Health Products
Adverse Reaction Information
Advisories, Warnings & Recalls
Biologics, Radio-
pharmaceuticals & Genetic Therapies
Compliance & Enforcement
Controlled Substances & Precursor Chemicals
Drug Products
International Activities
MedEffect
Medical Devices
Medical Use of Marihuana
Natural Health Products
Public Involvement & Consultations
Regulatory Requirements for Advertising
Special Access to Drugs & Health Products
Substances: Problematic Use
Veterinary Drugs
Legislation & Guidelines
Reports & Publications
Emergencies & Disasters
Environmental & Workplace Health
First Nations & Inuit Health
Food & Nutrition
Health Care System
Healthy Living
Science & Research
Government
Health Partners
Need
Larger
Text?
Home
>
Drugs & Health Products
>
MedEffect
>
Advisories, Warnings & Recalls
>
For Health Professionals
>
2004
2004
December
Important safety information on CELEBREX (celecoxib), increased cardiovascular risk
-Pfizer Canada Inc.
Date: 2004-12-22
Medication errors involving Reminyl and Amaryl
- Janssen-Ortho Inc. and Aventis Pharma Inc
Date: 2004-12-21
Medication errors involving Reminyl and Amaryl
- Janssen-Ortho Inc. and Aventis Pharma Inc
- Letter to pharmacists
Date: 2004-12-21
Serious Risk of Infection From Ultrasound and Medical Gels - Revision
Date: 2004-12-16
Updated safety : Possible relationship of Aredia and/or Zometa with osteonecrosis of the jaw
- Novartis Pharma Canada Inc.
Date: 2004-12-15
Bextra (valdecoxib) - Cardiovascular Risks and Serious Skin Reactions
- Pfizer Canada Inc.
Date: 2004-12-10
Updated Safety Information addressing the risk of malignancies associated with REMICADE (infliximab)
- Schering Canada Inc.
Date: 2004-12-02
November
Important Safety Update: Potential Effect of DEPO-PROVERA* (medroxyprogesterone acetate) on Bone Mineral Density
- Pfizer Canada Inc.
Date: 2004-11-22
Obligations of Pharmacists under the
Food and Drugs Act
and
Food and Drug Regulations
- letter to pharmacists
Date: 2004-11-16
Recall notification for all unused Advanced Bionics implantable cochlear stimulators.
- Advanced Bionics
Date: 2004-11-09
Drug stability failure of a few lots of Carbolith
®
150 mg capsules - Valeant Canada Limited
Date: 2004-11-04
October
New Safety Information Regarding PERMAX and Occurrence of Cardiac Valvulopathy / Fibrosis.
- Shire BioChem Inc.
Date: 2004-10-26
Update on Euro-K Recall Lot EKT 404 and Lot EKT 405
-Letter to pharmacist
Date: 2004-10-21
Risk of Serious Infection From Ultrasound and Medical Gels
- Notice to Hospitals
Date: 2004-10-20
Association of EPREX (epoetin alfa) with thrombotic vascular events
-Janssen-Ortho Inc.
Date: 2004-10-14
Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX
®
(rofecoxib)
-Merck Frosst Canada Ltd
- Letter to Pharmacists
Date: 2004-10-07
Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX
®
(rofecoxib)
-Merck Frosst Canada Ltd
Date: 2004-10-07
September
Important safety information for patients taking LAMICTAL (lamotrigine)
- GlaxoSmithKline Inc.
Date: 2004-09-27
Important Safety Information on Euro-K and Riva-K Sustained Release Potassium Supplements.
Date: 2004-09-01
August
Recall TAXUS Express Coronary Stent Systems and Express Coronary Stent Systems
- Boston Scientific
Date: 2004-08-16
July
Possible Association of RITUXAN (rituximab) with Hepatitis B reactivation
- Hoffmann-La Roche Limited
Date: 2004-07-30
Association of DESYREL (trazodone) with drug interactions with medications that alter CYP 3A4 metabolism
- Bristol-Myers Squibb Canada
Date: 2004-07-08
Product Recall Notice PROGLYCEM Suspension
- Schering Canada Inc.
Date: 2004-07-02
June
Possibility of sensitization to CIDEX OPA Solution with repeated exposure
- Johnson & Johnson Inc.
Date: 2004-06-24
ARAVA (leflunomide) and interstitial lung disease
Date: 2004-06-23
Health Canada releases important information on the dispensation of CLOZAPINE products in Canada
Date: 2004-06-23
Health Canada releases important information on the dispensation of CLOZAPINE products in Canada - Notice to Hospitals
Date: 2004-06-23
Important safety information regarding the association between CRESTOR (rosuvastatin) and rhabdomyolysis
Date: 2004-06-22
Health Canada Endorsed Important Safety Information on PRE-PEN
®
(benzylpenicilloyl polylysine injection USP) DIN: 00328693
- Omega Laboratories, Limited
Date: 2004-06-18
Important Safety Information on Hemodialysis Units and Blood Tubing Sets Incorporating a Transducer Protector
Date: 2004-06-11
Important drug safety information for WELLBUTRIN
®
SR and ZYBAN
®
(bupropion HCI): warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Biovail Pharmaceuticals Canada
Date: 2004-06-10
Important drug safety information for REMERON RD
TM
/REMERON
®
: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Organon Canada Ltd/Ltée
Date: 2004-06-02
Important drug safety information for LUVOX: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Solvay Pharma Inc.
Date: 2004-06-02
Important drug safety information for ZOLOFT: warning for SSRIs and other
newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Pfizer Canada Inc.
Date: 2004-06-02
Important drug safety information for EFFEXOR
®
: Warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Wyeth Pharmaceuticals
Date: 2004-06-02
Important drug safety information for Paroxetine: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- GlaxoSmithKline Inc.
Date: 2004-06-02
Important drug safety information for PROZAC: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Eli Lilly Canada Inc.
Date: 2004-06-02
Important drug safety information for CELEXA: warning for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm
- Lundbeck Canada Inc.
Date: 2004-06-02
May
Serious adverse reactions in pediatric patients treated with
ORTHOCLONE OKT*3 (muromonab-CD3)
- Janssen-Ortho Inc.
- Notice to Hospital
Date: 2004-05-13
Conditional Approval of Viread (tenofovir disoproxil fumarate)
- Gilead Sciences, Inc.
Date: 2004-05-10
Association of Absorbable Hemostatic Agents with paralysis or other neural deficits
- Notice to Hospitals
Date: 2004-05-07
Important Safety Update: Diarrhea and Ischemic Colitis in Patients Using ZELNORM (tegaserod hydrogen maleate)
- Novartis Pharmaceuticals Canada Inc.
Date: 2004-05-06
April
Inadequate Cleaning/Sterilization of EZ Clean Monobloc ACETABULAR REAMER
- Notice to Hospital
Date: 2004-04-23
Important Safety Information Regarding Reports of Serious Hepatic Events in Patients Receiving ACCOLATE
®
(zafirlukast)
- AstraZeneca Canada Inc.
Date: 2004-04-19
Health risks associated with use of INFUSION PUMPS
- Notice to Hospitals
Date: 2004-04-16
March
Important Drug Safety Information: ZYPREXA (olanzapine) and Cerebrovascular Adverse Events in Placebo-Controlled Elderly Dementia Trials
- Eli Lilly Canada Inc.
Date: 2004-03-17
Important New Safety Information Clarifying Risk Factors for Severe, Life-threatening and Fatal Hepatotoxicity with VIRAMUNE
®
(nevirapine)
- Boehringer Ingelheim (Canada) Ltd.
Date: 2004-03-12
Association of Tazocin
®
(piperacillin/tazobactam) with false positive results of the Bio-Rad
Aspergillus
Assay
- Wyeth Pharmaceuticals Canada
Date: 2004-03-09
February
Important Safety Information Regarding the Antiparkinson Drug PERMAX
®
(pergolide mesylate): Sudden Onset of Sleep
- Shire BioChem Inc.
Date: 2004-02-17
Important Safety Information Regarding TAMIFLU
®
(oseltamivir phosphate) and prescription in children less than 1 year of age
- Hoffmann-La Roche Limited
Date: 2004-02-09
January
Important safety information regarding a drug interaction between fluticasone propionate (Flonase /Flovent /Advair ) and ritonavir (Norvir /Kaletra )
- GlaxoSmithKline Inc.
Date: 2004-01-30
TOPAMAX* (topiramate) use is associated with Metabolic Acidosis
- Janssen-Ortho Inc.
Date: 2004-01-21
Important Drug Safety Information: EPREX (epoetin alfa) sterile solution: revised prescribing information for patients with chronic renal failure.
- Janssen-Ortho Inc.
Date: 2004-01-15
Important Safety Information Regarding the Use of SEVORANE AF (sevoflurane) in Conjunction with Anesthesia Machines
- Abbott Laboratories Limited
Date: 2004-01-08
Serious liver injury with TEBRAZID (pyrazinamide) or PMS-pyrazinamide and rifampin for the treatment of latent tuberculosis
- ICN Canada Limited and Pharmascience Inc.
Date: 2004-01-06
Last Updated: 2005-04-22
Important Notices